Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096780 | 0.73 | ICMT (0.38) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL28193567 | 0.63 | SLC6A4 (0.45) | CYP2A6TDP1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL26985761 | 0.63 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL10300805 | 0.63 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18288021 | 0.62 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL31172182 | 0.61 | SLC6A4 (0.46) | CYP2A6SLC6A4SLC6A3SLC6A2CYP1A2 | |
| SCHEMBL5617014 | 0.61 | TSHR (0.48) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19261793 | 0.60 | SLC6A4 (0.61) | SLC6A4SLC6A3SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL542484 | 0.60 | LMNA (0.70) | KMT2APOLBCYP2C9 | |
| SCHEMBL8222158 | 0.60 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160911-B2 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| US-20040204462-A1 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204462-A1 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | GPR119, HSD17B14, SLC2A1 | KMT2A 4669/4885CYP2A6 33/4885TDP1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.